370 related articles for article (PubMed ID: 21728912)
21. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
Renouf DJ; Lim HJ; Speers C; Villa D; Gill S; Blanke CD; O'Reilly SE; Kennecke H
Clin Colorectal Cancer; 2011 Jun; 10(2):97-101. PubMed ID: 21859560
[TBL] [Abstract][Full Text] [Related]
22. Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer.
Rautenberg T; Siebert U; Arnold D; Bennouna J; Kubicka S; Walzer S; Ngoh C
J Med Econ; 2014 Feb; 17(2):99-110. PubMed ID: 24215550
[TBL] [Abstract][Full Text] [Related]
23. Targeted agents to improve treatment results in colon cancer: bevacizumab and cetuximab.
Klein B; Gottfried M
J BUON; 2007 Sep; 12 Suppl 1():S127-36. PubMed ID: 17935270
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
25. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients.
De Stefano A; Carlomagno C; Pepe S; Bianco R; De Placido S
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1207-13. PubMed ID: 21409384
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of cetuximab in therapy of metastatic colorectal cancer: a system evaluation].
Hou SH; Liang XB; Bai WQ; Yang J; Yan D; Zhang X; Wang LC
Zhonghua Yi Xue Za Zhi; 2009 May; 89(20):1387-90. PubMed ID: 19671328
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
Whyte S; Pandor A; Stevenson M; Rees A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
[TBL] [Abstract][Full Text] [Related]
30. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
Duh MS; Dial E; Choueiri TK; Fournier AA; Antras L; Rodermund D; Neary MP; Oh WK
Curr Med Res Opin; 2009 Aug; 25(8):2081-90. PubMed ID: 19586325
[TBL] [Abstract][Full Text] [Related]
31. Third-line therapy for metastatic colorectal cancer.
Gundgaard MG; Soerensen JB; Ehrnrooth E
Cancer Chemother Pharmacol; 2008 Jan; 61(1):1-13. PubMed ID: 17786445
[TBL] [Abstract][Full Text] [Related]
32. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.
Rinaldi F; George E; Adler AI
Lancet Oncol; 2012 Mar; 13(3):233-4. PubMed ID: 22489288
[No Abstract] [Full Text] [Related]
33. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab and cetuximab for colorectal cancer.
Drug Ther Bull; 2006 May; 44(5):37-40. PubMed ID: 16706233
[TBL] [Abstract][Full Text] [Related]
35. Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer.
Macarulla T; Ramos FJ; Elez E; Capdevila J; Peralta S; Tabernero J
Clin Colorectal Cancer; 2008 Sep; 7(5):300-8. PubMed ID: 18794061
[TBL] [Abstract][Full Text] [Related]
36. Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies.
Saif MW; Kang SP; Chu E
Oncology (Williston Park); 2006 Dec; 20(14 Suppl 10):11-9. PubMed ID: 17354513
[TBL] [Abstract][Full Text] [Related]
37. [Study into the use of cetuximab in metastatic colorectal cancer in a third level hospital].
Marín Pozo JF; Oya Alvarez de Morales B; Caba Porras I; Aranda García J
Farm Hosp; 2009; 33(2):72-9. PubMed ID: 19480794
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.
Grothey A; Flick ED; Cohn AL; Bekaii-Saab TS; Bendell JC; Kozloff M; Roach N; Mun Y; Fish S; Hurwitz HI
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):726-34. PubMed ID: 24830357
[TBL] [Abstract][Full Text] [Related]
39. Cetuximab for the first-line treatment of metastatic colorectal cancer.
Meads C; Round J; Tubeuf S; Moore D; Pennant M; Bayliss S
Health Technol Assess; 2010 May; 14 Suppl 1():1-8. PubMed ID: 20507797
[TBL] [Abstract][Full Text] [Related]
40. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]